Ceribell Files Complaints Against Natus Med.

By Hao Liu • Tuesday, July 08 10:16 • Permanent Link

Ceribell, Inc. (NASDAQ: CBLL) has announced the filing of complaints against Natus Medical Incorporated and its subsidiaries, alleging patent infringement and unfair competition. The complaints have been filed with the U.S. International Trade Commission (USITC) and the U.S. District Court in Delaware.

The complaints assert infringement of six patents related to important features of Ceribell's point-of-care electroencephalography (EEG) headband and electrode design. Ceribell has requested the USITC to investigate its claims and issue an exclusion order to bar the importation of any infringing Natus products into the United States.

Jane Chao, Ph.D., co-founder and CEO of Ceribell, emphasized the company's significant investments in point-of-care EEG technology and its commitment to fair competition. Ceribell aims to vigorously protect its intellectual property against infringement to continue delivering leading-edge products to healthcare professionals and their patients. The market has reacted to these announcements by moving the company's shares -9.14% to a price of $17.20. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.